Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Clinical Case ReportsOpen Access

Dermatopathological Findings of an Erythema Multiforme‐Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRyunosuke MurofushiYKYoichiro KatoTSTakashi Seo

Discussion

Loading...

Member takes

Overview

A case report identifies skin reactions to enfortumab vedotin and pembrolizumab treatment, indicating the need for careful management.

Key Points

  • This report aims to elucidate the dermatopathological features of a skin eruption associated with enfortumab vedotin and pembrolizumab therapy in metastatic urothelial carcinoma.
  • Described a 69-year-old male patient with metastatic renal pelvic cancer.
  • Evaluated skin biopsy findings using immunohistochemistry.
  • Monitored peripheral blood tests for changes in monocytes and eosinophils alongside clinical symptoms.
  • Managed skin eruption through corticosteroids and adjusted therapy doses.
  • Grade 3 erythema multiforme-like drug eruption was observed on day 8 of cycle 3.
  • Biopsy showed improvement in proliferative activity correlating with clinical improvement.
  • Partial response of metastatic lesions was maintained despite skin toxicity.
  • A grade 2 rash recurred but was managed successfully, allowing for continued therapy.

Cite This Study

Murofushi et al. (2026) studied this question.

synapsesocial.com/papers/69d1fde4a79560c99a0a4435https://doi.org/10.1002/ccr3.71950
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enfortumab vedotin‐induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature2024 · 14 citations
  2. 2Enfortumab Vedotin Drug Eruption: Cutaneous Adverse Events and Histopathologic Findings2024 · 3 citations
  3. 3Enfortumab Vedotin–Related Cutaneous Adverse Events: Two Cases Highlighting Ring Mitosis and Severity‐Guided Management2026 · 1 citations
  4. 4Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report2026 · 2 citations
  5. 5Erythema Multiforme Associated With Pembrolizumab Treatment for Recurrent Urothelial Carcinoma: A Case Report2026 · 1 citations